Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,279 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infection Prophylaxis Clear all

Conditions: Dental Plaque
Interventions: 19416-154-1, W002194-0221P; Device
Lead sponsor: Johnson & Johnson Consumer and Personal Products Worldwide; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Adult Primary Liver Cancer, Hepatitis C Infection
Interventions: S-adenosyl-L-methionine disulfate p-toluene-sulfonate, placebo, laboratory biomarker analysis, immunoenzyme technique, high performance liquid chromatography; Drug · Other
Lead sponsor: Chao Family Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 5
States / cities: Tucson, Arizona • Long Beach, California • Los Angeles, California + 2 more

Conditions: Tobacco Use Cessation
Interventions: Nicotine Patch, Questionnaires, Pamphlet, Phone Counseling Sessions, Saliva Test, Smart phone; Drug · Behavioral · Other + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: SARS-CoV-2 Infection
Interventions: COVID Prevention Program (CPP); Behavioral
Lead sponsor: San Diego State University; Other
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Cytomegalovirus, Organ Transplant, Kidney Transplant; Complications, Liver Transplant Complications, Simultaneous Liver-Kidney Transplantation; Complications
Interventions: Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months; Drug
Lead sponsor: Camille N. Kotton, MD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • Dallas, Texas

Conditions: Pregnancy, Sexually Transmitted Infections
Interventions: Motivational Intervention, Didactic Educational Intervention; Behavioral
Lead sponsor: University of Rhode Island; Other
Eligibility: 14 Years to 21 Years · Female only
Enrollment: 272 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 5
States / cities: Cranston, Rhode Island • Exeter, Rhode Island • Providence, Rhode Island + 1 more

Conditions: Influenza, Healthy Volunteers
Interventions: Panblok + MF59 Dose 1, Panblok + MF59 Dose 2, Unadjuvanted Panblok Dose 3; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 581 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 16
States / cities: Mesa, Arizona • Hallandale, Florida • Hollywood, Florida + 11 more

Conditions: Recurrent UTIs, Recurrent Urinary Tract Infections, Recurrent Urinary Tract Infections in Women, Recurrent Urinary Tract Infection, Cystitis Recurrent, Cystitis Chronic, UTI, UTI - Urinary Tract Infection, UTI - Lower Urinary Tract Infection
Interventions: D-Mannose, Placebo; Dietary Supplement
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 55 Years to 85 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: HIV, AIDS
Interventions: MOVE Intervention, H4L Comparison Intervention; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 24 Years · Male only
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: Los Angeles, California • Chicago, Illinois • The Bronx, New York + 2 more

Conditions: Surgical Site Infection
Interventions: Implementation of the AO Trauma SSI Prevention Bundle; Behavioral
Lead sponsor: AO Clinical Investigation and Publishing Documentation; Other
Eligibility: 18 Years to 100 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 8
States / cities: Los Angeles, California • Lexington, Kentucky • Worcester, Massachusetts + 5 more

Conditions: Respiratory Syncytial Virus Infection Prevention
Interventions: Ad26.RSV.preF-based Vaccine, Placebo; Biological · Other
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 1,124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Coral Gables, Florida • Miami, Florida • El Dorado, Kansas + 4 more

Conditions: Influenza
Interventions: Trivalent influenza virus vaccine, Placebo; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 3
States / cities: Daytona Beach, Florida • Portland, Oregon • Austin, Texas

Conditions: Hiv, Adolescent Behavior, Family Relations, Sexual Orientation
Interventions: MySTYLE, Waitlist Control; Behavioral · Other
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 14 Years to 20 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma, Health Status Unknown, Human Papillomavirus Infection, Malignant Neoplasm
Interventions: Informational Intervention; Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Cytomegalovirus Disease
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 1 Hour to 5 Days
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: HIV Infections
Interventions: Infección de Amor (Infectious Love); Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Cesarean Section, Infection
Interventions: Cefazolin (Timing of Antibiotic Prophylaxis); Drug
Lead sponsor: MemorialCare; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Long Beach, California • Orange, California

Conditions: Shoulder Arthropathy Associated With Other Conditions, Shoulder Arthritis, Shoulder Osteoarthritis, Shoulder Pain
Interventions: Jumpstart Dressing, Standard Dressing; Device · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Clostridioides Difficile Infection
Interventions: LMN-201, Placebo; Drug
Lead sponsor: Lumen Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 15
States / cities: Escondido, California • Hamden, Connecticut • Tampa, Florida + 12 more

Conditions: Chronic Hepatitis B
Interventions: FTC/TDF, Hepatitis B Immunoglobulin (HBIg); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Atlanta, Georgia + 2 more

Conditions: Social Stigma, Substance Use Disorders, HIV Infections, Physician-Patient Relations
Interventions: Substance use stigma training; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Avian Influenza
Interventions: ND1.1; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Catheter Related Infections, Short Bowel Syndrome
Interventions: 70% ethanol; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 3 Months and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neonatal Staphylococcal Sepsis
Interventions: Pagibaximab (formerly BSYX-A110); Drug
Lead sponsor: Biosynexus Incorporated; Industry
Eligibility: 3 Days to 7 Days
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

A Four-Week Study to Measure the Effectiveness of an Experimental Mouthwash Used After Teeth Cleaning

Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection

Mobile Media-Rich Interactive Guideline System (MMRIGS) Pilot Study

Intervention to Prevent Household and Community Spread of COVID-19 Among Latinos

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

Contraceptive Awareness and Reproductive Education

Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older

A Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections

Testing a Secondary Prevention Intervention for HIV-Positive Black Young Men Who Have Sex With Men

AO Multicenter Intervention Trial for Prevention of Surgical Site Infection

A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection

A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine

MySTYLE: Online Family-based HIV Prevention for Non-heterosexual Black Adolescent Males in the South

CATCH-UP Intervention in Increasing Cancer Screening and Prevention Care in Uninsured Patients at Community Health Centers

TT-CMV Observational Birth Cohort Study

Impact of a Telenovela/Soap Opera for HIV Prevention in Latinas

Trial Comparing the Optimal Timing of Antibiotic Prophylaxis at the Time of Cesarean Delivery

Microcurrent Dressing to Treat Infections, Before, During and After Surgery

LMN-201 for Prevention of C. Difficile Infection Recurrence

Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant

Planning a Multi-Level Intervention to Reduce Substance Use Stigma in HIV Prevention and Care

Immunogenicity of ND1.1 by Delivery Directly to the Ileum

Trial of 70% Ethanol Versus Heparin to Reduce the Rate of Central Line Infections in Children With Short Bowel Syndrome

Safety and Pharmacokinetics Study in VLBW Neonates With BSYX-A110